Payment overview · 2025
General Payments
$486.22
29 reported records · 6 companies
Healthcare provider profile · identity verified
John E Thurston, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · WORLAND, WY · NPI 1144296245
Verified facts
What the public records show
CMS Open Payments records show John E Thurston, M.D. received $486.22 in general payments during 2025 across 29 reported records.
Lilly USA, LLC accounted for 33.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $163.91 | 33.7% | 11 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $108.83 | 22.4% | 6 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $87.86 | 18.1% | 5 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $75.48 | 15.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.66 | 6.1% | 2 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $20.48 | 4.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $486.22 | 29 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $163.91 | 11 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $146.12 | 10 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $75.78 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $75.78 | 4 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $75.48 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $50.31 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $33.05 | 2 | 2025 |
Source payment records
|
|||||
| GAMMA Normalized: gamma |
Device | Stryker Corporation | $20.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 11 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
97 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
127 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 555 | 131 |
| Atorvastatin Calcium | Atorvastatin Calcium | 437 | 116 |
| Losartan Potassium | Losartan Potassium | 333 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 308 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 299 | 78 |
| Gabapentin | Gabapentin | 288 | 58 |
| Furosemide | Furosemide | 262 | 70 |
| Pantoprazole Sodium | Pantoprazole Sodium | 262 | 77 |
| Lisinopril | Lisinopril | 254 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 246 | 59 |
| Potassium Chloride | Potassium Chloride | 229 | 55 |
| Sertraline Hcl | Sertraline Hcl | 190 | 40 |
| Omeprazole | Omeprazole | 174 | 51 |
| Tamsulosin Hcl | Tamsulosin Hcl | 164 | 51 |
| Eliquis | Apixaban | 152 | 24 |
| Metformin Hcl | Metformin Hcl | 146 | 39 |
| Pioglitazone Hcl | Pioglitazone Hcl | 143 | 43 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 131 | 35 |
| Ozempic | Semaglutide | 127 | 16 |
| Warfarin Sodium | Warfarin Sodium | 126 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 124 | 35 |
| Cephalexin | Cephalexin | 123 | 92 |
| Metformin Hcl Er | Metformin Hcl | 123 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 30 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 120 | 21 |
| Pravastatin Sodium | Pravastatin Sodium | 118 | 34 |
| Quetiapine Fumarate | Quetiapine Fumarate | 109 | 14 |
| Ezetimibe | Ezetimibe | 107 | 31 |
| Pregabalin | Pregabalin | 105 | 25 |
| Azithromycin | Azithromycin | 101 | 77 |
| Jardiance | Empagliflozin | 97 | 16 |
| Meloxicam | Meloxicam | 96 | 37 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 34 |
| Trazodone Hcl | Trazodone Hcl | 93 | 24 |
| Allopurinol | Allopurinol | 87 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 86 | 22 |
| Montelukast Sodium | Montelukast Sodium | 83 | 21 |
| Mirtazapine | Mirtazapine | 81 | 14 |
| Tramadol Hcl | Tramadol Hcl | 79 | 25 |
| Simvastatin | Simvastatin | 77 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 76 | 21 |
| Atenolol | Atenolol | 73 | 23 |
| Carvedilol | Carvedilol | 73 | 17 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 70 | 26 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 18 |
| Propranolol Hcl Er | Propranolol Hcl | 67 | 14 |
| Citalopram Hbr | Citalopram Hydrobromide | 64 | 20 |
| Donepezil Hcl | Donepezil Hcl | 63 | 13 |
| Farxiga | Dapagliflozin Propanediol | 61 | 11 |
| Fluconazole | Fluconazole | 60 | 36 |
| Zolpidem Tartrate | Zolpidem Tartrate | 59 | 14 |
| Prednisone | Prednisone | 58 | 41 |
| Duloxetine Hcl | Duloxetine Hcl | 57 | 18 |
| Lorazepam | Lorazepam | 57 | 12 |
| Synthroid | Levothyroxine Sodium | 57 | 14 |
| Finasteride | Finasteride | 56 | 20 |
| Entresto | Sacubitril/Valsartan | 55 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 54 | 20 |
| Repatha Sureclick | Evolocumab | 54 | suppressed |
| Sucralfate | Sucralfate | 50 | 16 |
| Methadone Hcl | Methadone Hcl | 48 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 48 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 46 | 14 |
| Clonidine Hcl | Clonidine Hcl | 46 | 13 |
| Methylphenidate Hcl | Methylphenidate Hcl | 44 | suppressed |
| Glipizide Er | Glipizide | 43 | 13 |
| Irbesartan | Irbesartan | 43 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 15 |
| Famotidine | Famotidine | 41 | 15 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 40 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 40 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 40 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 39 | suppressed |
| Betamethasone Diprop Augmented | Betamethasone/Propylene Glyc | 36 | 28 |
| Breo Ellipta | Fluticasone/Vilanterol | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 22 |
| Trulicity | Dulaglutide | 35 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Xarelto | Rivaroxaban | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 33 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 33 | suppressed |
| Levetiracetam | Levetiracetam | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Spironolactone | Spironolactone | 33 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 32 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 32 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 32 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 31 | suppressed |
| Celecoxib | Celecoxib | 30 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 25 |
| Estradiol | Estradiol | 30 | 11 |
| Alendronate Sodium | Alendronate Sodium | 29 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 29 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Alprazolam | Alprazolam | 28 | 12 |
| Clotrimazole | Clotrimazole | 28 | 15 |
| Doxazosin Mesylate | Doxazosin Mesylate | 27 | suppressed |
| Mounjaro | Tirzepatide | 27 | suppressed |
| Colchicine | Colchicine | 26 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 26 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 25 | 14 |
| Nystatin | Nystatin | 25 | suppressed |
| Amoxicillin | Amoxicillin | 24 | 20 |
| Dexamethasone | Dexamethasone | 24 | 20 |
| Baclofen | Baclofen | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 21 | suppressed |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | 11 |
| Fentanyl | Fentanyl | 20 | suppressed |
| Haloperidol | Haloperidol | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 20 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | suppressed |
| Bupropion Xl | Bupropion Hcl | 19 | suppressed |
| Felodipine Er | Felodipine | 19 | suppressed |
| Indomethacin | Indomethacin | 19 | suppressed |
| Methylprednisolone | Methylprednisolone | 19 | 15 |
| Nifedipine Er | Nifedipine | 19 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 19 | suppressed |
| Glimepiride | Glimepiride | 18 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Januvia | Sitagliptin Phosphate | 18 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 17 | 13 |
| Dulera | Mometasone/Formoterol | 17 | suppressed |
| Lamotrigine | Lamotrigine | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 17 | suppressed |
| Savella | Milnacipran Hcl | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Bumetanide | Bumetanide | 16 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 16 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 16 | 11 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 13 |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 14 | suppressed |
| Insulin Degludec Pen (U-200) | Insulin Degludec | 14 | suppressed |
| Invokana | Canagliflozin | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 13 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 13 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 12 | suppressed |
| Armour Thyroid | Thyroid,pork | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 11 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 11 | suppressed |
| Methimazole | Methimazole | 11 | suppressed |
| Ondansetron Odt | Ondansetron | 11 | suppressed |
| Praluent Pen | Alirocumab | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $486.22 · 29 records | Lilly USA, LLC | BREZTRI, EVENITY, GAMMA, MOUNJARO, OTEZLA, REPATHA, VERQUVO, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error